What You Should Know:
What You Should Know:
– LCP Health Analytics is partnering with COTA to explore how US real-world data (RWD) can support health technology assessments (HTA) in the United Kingdom (UK) and European Union (EU).
– With growing recognition that European patients may be underserved by delays in accessing new health technologies, this initiative explores whether deidentified US multiple myeloma patient data can be leveraged to inform reimbursement decisions and accelerate access to new treatments in the UK.
LCP and COTA Partner to Advance Real-World Evidence Use in Cross-Country Oncology HTAs
Fusing Analytics with Global Real-World Data for Meaningful Insights
With market-leading expertise across pensions, financial services, energy, health, and sports analytics, LCP continues to help clients navigate complexity and unlock opportunity. Their data-driven, impact-oriented approach blends human judgement with deep analytical capability to support decisions that matter—for businesses and society alike.
In a groundbreaking collaboration, LCP Health Analytics is partnering with COTA to align US real-world oncology data with UK health technology assessment (HTA) requirements. By integrating COTA’s robust US oncology dataset with LCP’s health analytics and HTA evaluation expertise, the partnership marks the first-ever direct comparison between US and UK real-world haematological oncology data.
Bridging the UK–US Data Divide in Oncology HTAs
The project will explore how US-derived patient data can be used to emulate NHS-relevant cohorts for UK and EU HTA submissions, addressing a longstanding barrier in the application of international data to local health policy. Key components of the project include:
· Identifying patient subgroups in the US who resemble NHS-treated populations using demographic and clinical characteristics
· Analyzing treatment patterns and outcomes, such as survival, to determine payer- and HTA-relevant metrics
· Assessing the feasibility of using these groups to emulate clinical trial populations in future real-world studies
“By combining UK and US healthcare data and expertise, we can generate evidence to support HTA submissions and hopefully expedite access to new treatments,” said Dr Ben Bray, Partner and Evidence Generation Lead at LCP Health Analytics. “We hope to see more collaborative efforts like this in the future.”
COTA’s Contribution to Scalable, AI-Driven Oncology Insights
COTA’s real-world data is drawn from a 50/50 split of academic and community oncology care settings across the US. Its proprietary AI-driven abstraction and curation tools will enable scalable insights by streamlining data cleaning and cohort generation.
This partnership builds on LCP Health Analytics’ recent US expansion with the launch of their US Access Solutions in June, reinforcing their commitment to improving global health access pathways through robust data and evidence generation.
Toward a Future of Smarter, Faster, Cross-Border Evidence Generation
For years, UK regulatory and HTA bodies have depended on US clinical trial data while simultaneously demanding more relevant, country-specific real-world evidence. This initiative aims to close that gap by establishing new methodologies for cross-country alignment—bringing the right treatments to the right patients, faster.
